Navigation Links
Prevention And Control Of Diabetes Crucial To Indian Population

In a first ever study conducted on the prevalence of diabetes in the Indian population, several important aspects of control and prevention of diabetes has been uncovered. // So far, such studies have only been conducted on Western population, the results of which cannot be applied to South Asians.

The research has been conducted by M V Hospital for Diabetes and Diabetes Research Centre, an association of the World Health Organization Collaborating Centre for Diabetes in India. Dr. A. Ramachandran, a senior scientist has conducted the study, the results of which can be found in Diabetologia, the International Journal of Diabetes.

It has been found that more than 35 million Indians suffer from diabetes. Alarmingly, as much as 13 million cases (50% in rural India and 30% in urban India) remains undiagnosed, leading to long-term complications. Various factors such as widespread urbanization, reduced physical activity, the consequent obesity, stress and several other environmental factors have been accounted for the high incidence of diabetes in India.

Diabetes is next only to smoking, in causing cardiovascular disease in the Indian population. The prevalence of diabetes is greater amongst the urban South Asian population (12-15%) compared to urban population in the West (6%). Alarmingly, the incidence of diabetes in urban India has increased by a margin of 20 times over the past two decades.

Moreover, measures such as weight reduction; life style modification may not hold good for the Indian population, as Indians are diverse with respect to human body measurement and biochemical constitution. Indians develop diabetes at an early age compared to the Western population, probably because they are highly insulin resistant.

More than 11,00 high-risk individuals were continuously monitored during the study based on their lifestyle. The study participants were divided into four groups. The control group was free of medicatio
'"/>




Page: 1 2

Related medicine news :

1. Prevention is better than cure
2. Prevention of cataracts
3. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
4. Simple Stroke Prevention is Best
5. Prevention of Prostate Cancer
6. Prevention of Rickets
7. Prevention of Vision Loss
8. Suicide Prevention Program – Having its Intended Effec
9. The Key To Prevention Of Heart Disease In Adults
10. Stroke Prevention
11. Prevention Of Recurrent Leg Ulcers
Post Your Comments:
Other Medicine News:Health News:Secretary Shinseki Announces $215 Million in Projects for Rural Veterans 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 2Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 3Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 4Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 5Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 6Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 7Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 8Health News:FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia 9Health News:Blue Cross and Blue Shield of Georgia and Piedmont Healthcare Announce Contract Renewal 2Health News:Thousands of Canada's best minds converge at Congress 2009 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 3Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 2Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 3
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 1Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 2Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 62575 1Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 62575 2VIDEO from Medialink and the American Nurses Association 28ANA 29 3A American Nurses Association Urges All Americans to Take Part in Health Care Refo 62572 1VIDEO from Medialink and the American Nurses Association 28ANA 29 3A American Nurses Association Urges All Americans to Take Part in Health Care Refo 62572 2